106 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
SHPG Shire plc $176.25 $46.08B N/A
Article Searches
Takeda Shareholders Approve $62 Billion Shire Bid https://www.wsj.com/articles/takeda-wins-shareholder-approval-for-its-62-billion-shire-bid-1543982265?mod=pls_whats_news_us_business_f Dec 05, 2018 - The approval from Takeda Pharmaceutical’s shareholders for the Shire bid clears the path for the biggest-ever overseas acquisition by a Japanese company.
Shire's Takhzyro Gets European Nod for Hereditary Angioedema http://www.zacks.com/stock/news/340828/shires-takhzyro-gets-european-nod-for-hereditary-angioedema?cid=CS-ZC-FT-340828 Dec 03, 2018 - Shire's (SHPG) gets European approval for Takhzyro subcutaneous injection, for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.
Shire's Filing Accepted by FDA for Gattex's Label Expansion http://www.zacks.com/stock/news/337411/shires-filing-accepted-by-fda-for-gattexs-label-expansion?cid=CS-ZC-FT-337411 Nov 14, 2018 - The FDA accepts Shire's (SHPG) sNDA and is expected to take action in March 2019.
Shire Plc (SHPG) Q3 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4217067-shire-plc-shpg-q3-2018-results-earnings-call-transcript?source=feed_sector_healthcare Nov 01, 2018 - Shire Plc (NASDAQ:SHPG)Q3 2018 Earnings CallNovember 01, 2018 10:00 am ETExecutivesChristoph Brackmann - Shire PlcFlemming Ornskov - Shire PlcThomas J. W. Dittrich - Shire PlcAnalystsJo Walton - Credi
J&J's Stelara Succeeds in Phase III Ulcerative Colitis Study http://www.zacks.com/stock/news/327253/jjs-stelara-succeeds-in-phase-iii-ulcerative-colitis-study?cid=CS-ZC-FT-327253 Oct 10, 2018 - J&J's (JNJ) Stelara induces clinical remission and response in ulcerative colitis patients who had failed prior therapy, per data from a phase III study.
Aldeyra Surges on Positive Dry Eye Study Data on Reproxalap http://www.zacks.com/stock/news/325203/aldeyra-surges-on-positive-dry-eye-study-data-on-reproxalap?cid=CS-ZC-FT-325203 Sep 27, 2018 - Aldeyra Therapeutics' (ALDX) dry eye candidate, reproxalap, achieves early onset of improvement in patients and a broad range of activity.
Is Shire (SHPG) a Suitable Stock for Value Investors Now? http://www.zacks.com/stock/news/324295/is-shire-shpg-a-suitable-stock-for-value-investors-now?cid=CS-ZC-FT-324295 Sep 21, 2018 - Let's see if Shire plc (SHPG) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Company News For Sep 17, 2018 http://www.zacks.com/stock/news/323354/company-news-for-sep-17-2018?cid=CS-ZC--323354 Sep 17, 2018 - Companies In The News are: ADBE,LB,NI,SHPG
Shire's ADHD Portfolio Remains Strong Amid Competition http://www.zacks.com/stock/news/322375/shires-adhd-portfolio-remains-strong-amid-competition?cid=CS-ZC-FT-322375 Sep 10, 2018 - Shire (SHPG) has a strong hold in the attention deficit hyperactivity disorder (ADHD) market despite facing competition.
Company News For Jul 11, 2018 http://www.zacks.com/stock/news/311095/company-news-for-jul-11-2018?cid=CS-ZC--311095 Jul 11, 2018 - Companies In The News are: SHPG,SJM,XRX,PCAR

Pages: 123456...11

Page 1>